


Cat No. 36-F52

LDN193189

2mg

LDN193189 is a highly potent small molecule BMP inhibitor. It inhibits BMP type I receptors ALK2, ALK3 and ALK6. LDN193189 was derived from structure-activity relationship studies of Dorsomorphin and functions by preventing phosphorylation of Smad1, Smad5 and Smad8. It shows in vivo clinical utility by reducing ectopic ossification in mouse models.

TECHNICAL INFORMATION



Other Names: DM-3189, 6-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-3-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidine hydrochloride

Chemical Formula: C₂₅H₂₂N₆ HCl

CAS Number: 1062368-24-4

Molecular Weight: 442.94

Purity: 99% pure

Appearance: Yellow/Orange Powder

Solubility: DMSO and methanol



For research purposes only

STORAGE AND HANDLING

Storage: Store at 4°C and protected from light. Following reconstitution, store aliquots at -20°C.

Stability: Stock solutions stable at -20°C for up to 2 years.

Shipping Conditions: Shipped at room temperature.

PRODUCT USE

Soluble in DMSO. For a 10mM concentrated stock solution, reconstitute the compound by adding 452 µl of DMSO to the entire contents of the vial. Vortex for 5 minutes.

REFERENCES

1. Yu et al. (2008) BMP type I receptor inhibition reduces heterotopic ossification. *Nature Med.* 14: 1363-1369.
2. Cuny et al. (2008) Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors. (18)15:4388-92.
3. Yu et al. (2008) Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. *Nature Chem Biol.* 4: 33-41.